Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug–drug interaction studies

被引：0
|
作者：
Shuying Yang
Misba Beerahee
机构：
[1] GlaxoSmithKline,Clinical Pharmacology Modelling and Simulation, Research & Development
来源：
European Journal of Clinical Pharmacology | 2011年 / 67卷
关键词：
Clinical trial simulation population pharmacokinetic analysis; Drug–drug interaction; Sample size; Power;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：225 / 233
页数：8
相关论文
共 50 条
  • [41] Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data
    Frederiksen, Trine
    Smith, Robert L.
    Wollmann, Birgit M.
    Areberg, Johan
    Molden, Espen
    CLINICAL PHARMACOKINETICS, 2021, 60 (11) : 1475 - 1486
  • [42] Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data
    Trine Frederiksen
    Robert L. Smith
    Birgit M. Wollmann
    Johan Areberg
    Espen Molden
    Clinical Pharmacokinetics, 2021, 60 : 1475 - 1486
  • [43] Application of MD-simulations in GPCR drug design - exemplified by case studies
    Tautermann, Christofer
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [44] APPLICATION OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL FOR PREDICTION OF THE DRUG-DRUG INTERACTION (DDI) BETWEEN LORAZEPAM AND PROBENECID
    Neuhoff, Sibylle
    Musther, Helen
    Rowland-Yeo, Karen
    DRUG METABOLISM REVIEWS, 2015, 47 : 121 - 121
  • [45] A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug-Drug Interaction Studies
    Hanke, Nina
    Tuerk, Denise
    Selzer, Dominik
    Wiebe, Sabrina
    Fernandez, Eric
    Stopfer, Peter
    Nock, Valerie
    Lehr, Thorsten
    PHARMACEUTICS, 2020, 12 (06) : 1 - 19
  • [46] Simultaneous Determination of Losartan and Rosuvastatin in Rat Plasma Using Liquid Chromatography–Tandem Mass Spectrometric Technique for Application into Pharmacokinetic and Drug–Drug Interaction Studies
    Magdy Atef Wadie
    Safaa M. Kishk
    Khaled M. Darwish
    Samia M. Mostafa
    Mohamed Saleh Elgawish
    Chromatographia, 2020, 83 : 1477 - 1494
  • [47] Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population
    Khaled Abduljalil
    Xian Pan
    Amita Pansari
    Masoud Jamei
    Trevor N. Johnson
    Clinical Pharmacokinetics, 2020, 59 : 501 - 518
  • [48] Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population
    Abduljalil, Khaled
    Pan, Xian
    Pansari, Amita
    Jamei, Masoud
    Johnson, Trevor N.
    CLINICAL PHARMACOKINETICS, 2020, 59 (04) : 501 - 518
  • [49] Development of a Physiologically Based Pharmacokinetic Population Model for Diabetic Patients and its Application to Understand Disease-drug-drug Interactions
    Li, Yafen
    Li, Xiaonan
    Zhu, Miao
    Liu, Huan
    Lei, Zihan
    Yao, Xueting
    Liu, Dongyang
    CLINICAL PHARMACOKINETICS, 2024, 63 (06) : 831 - 845
  • [50] Assessment of Drug-drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model
    Sakai, Shuhei
    Kobuchi, Shinji
    Ito, Yukako
    Sakaeda, Toshiyuki
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 111 (05) : 1522 - 1530
12345